Company intelligence / Profile preview

Purevision

Wenzhou, Zhejiang, Chinaglobal.medical.canon ↗

Ownership: Private
Development stage: Commercial

Overview

Purevision develops ophthalmic medical devices focused on providing innovative treatment options for glaucoma patients. The company's main product line includes glaucoma treatment stents. It was founded in 2020 and remains at an early stage with backing from notable investors such as Qiming Venture Partners and REDHILL CAPITAL. No published clinical trial results are available yet; the company appears to be pre-commercialization[1].

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Purevision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Purevision.

Explore the full profile